These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
205 related articles for article (PubMed ID: 19642026)
21. Intravenous immunoglobulin vs plasma exchange in treatment of mechanically ventilated adults with Guillain-Barré syndrome. Charra B; Hachimi A; Benslama A; Motaouakkil S Pan Afr Med J; 2014; 18():35. PubMed ID: 25368724 [TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of Guillain-Barré syndrome. Liu S; Dong C; Ubogu EE Hum Vaccin Immunother; 2018; 14(11):2568-2579. PubMed ID: 29953326 [TBL] [Abstract][Full Text] [Related]
23. Functional outcomes following inpatient rehabilitation of Guillain-Barré syndrome patients: Intravenous immunoglobulins versus plasma exchange. Bondi M; Engel-Haber E; Wolff J; Grosman-Rimon L; Bloch A; Zeilig G NeuroRehabilitation; 2021; 48(4):543-551. PubMed ID: 34024788 [TBL] [Abstract][Full Text] [Related]
24. Changes in the severity and subtype of Guillain-Barré syndrome admitted to a specialist Neuromedical ICU over a 25 year period. Taylor CJ; Hirsch NP; Kullmann DM; Howard RS J Neurol; 2017 Mar; 264(3):564-569. PubMed ID: 28091723 [TBL] [Abstract][Full Text] [Related]
25. Short-Term Prognosis of Mechanically Ventilated Patients With Guillain-Barré Syndrome Is Worsened by Corticosteroids as an Add-On Therapy. Wu X; Zhang B; Li C; Shen D; Liu K; Zhu J; Zhang HL Medicine (Baltimore); 2015 Oct; 94(43):e1898. PubMed ID: 26512609 [TBL] [Abstract][Full Text] [Related]
26. Diagnosis, treatment and prognosis of Guillain-Barré syndrome (GBS). van Doorn PA Presse Med; 2013 Jun; 42(6 Pt 2):e193-201. PubMed ID: 23628447 [TBL] [Abstract][Full Text] [Related]
27. Is a second cycle of immunoglobulin justified in axonal forms of Guillain-Barré syndrome? Godoy DA; Rabinstein A Arq Neuropsiquiatr; 2015 Oct; 73(10):848-51. PubMed ID: 26465402 [TBL] [Abstract][Full Text] [Related]
28. Predictors of Treatment Outcome and Clinical Profile among Guillain- Barre Syndrome Patients in South India. Joseph N; Shrigiri S Rev Recent Clin Trials; 2023; 18(4):258-268. PubMed ID: 37907491 [TBL] [Abstract][Full Text] [Related]
29. Prominent plasmacytosis following intravenous immunoglobulin correlates with clinical improvement in Guillain-Barré syndrome. Mori I; Parizot C; Dorgham K; Demeret S; Amoura Z; Bolgert F; Gorochov G PLoS One; 2008 May; 3(5):e2109. PubMed ID: 18461177 [TBL] [Abstract][Full Text] [Related]
30. IgG Fc N-glycosylation in Guillain-Barré syndrome treated with immunoglobulins. Fokkink WJ; Selman MH; Dortland JR; Durmuş B; Kuitwaard K; Huizinga R; van Rijs W; Tio-Gillen AP; van Doorn PA; Deelder AM; Wuhrer M; Jacobs BC J Proteome Res; 2014 Mar; 13(3):1722-30. PubMed ID: 24533874 [TBL] [Abstract][Full Text] [Related]
31. Therapeutic plasma exchange in patients with neurologic diseases: retrospective multicenter study. Kaynar L; Altuntas F; Aydogdu I; Turgut B; Kocyigit I; Hacioglu SK; Ismailogullari S; Turgut N; Erkurt MA; Sari I; Oztekin M; Solmaz M; Eser B; Ersoy AO; Unal A; Cetin M Transfus Apher Sci; 2008 Apr; 38(2):109-15. PubMed ID: 18331814 [TBL] [Abstract][Full Text] [Related]
32. A simple functional marker to predict the need for prolonged mechanical ventilation in patients with Guillain-Barré syndrome. Fourrier F; Robriquet L; Hurtevent JF; Spagnolo S Crit Care; 2011; 15(1):R65. PubMed ID: 21338488 [TBL] [Abstract][Full Text] [Related]
33. Albumin levels as a biomarker for second Intravenous Immunoglobulin (IVIG) treatment in Guillain-Barre syndrome (GBS). Shalman A; Savir S; Mechnik Steen Y; Ovanyan A; Boniel N; Koyfman L; Bichovsky Y; Zlotnik A; Klein M; Brotfain E J Clin Neurosci; 2020 Apr; 74():247-249. PubMed ID: 32088107 [TBL] [Abstract][Full Text] [Related]
35. Guillain-Barré syndrome: clinical features, treatment choices and outcomes in an Australian cohort. Barnes SL; Herkes GK Intern Med J; 2020 Dec; 50(12):1500-1504. PubMed ID: 31760675 [TBL] [Abstract][Full Text] [Related]
36. Plasma exchange (PE) versus intravenous immunoglobulin (IVIG) for the treatment of Guillain-Barré syndrome (GBS) in patients with severe symptoms: A systematic review and meta-analysis. Zaki HA; Iftikhar H; Najam M; Masood M; Al-Marri NDR; Elgassim MAM; Fayed M; Shaban EE eNeurologicalSci; 2023 Jun; 31():100468. PubMed ID: 37288440 [TBL] [Abstract][Full Text] [Related]
37. Effect of human immunodeficiency virus on intensive care unit outcome of patients with Guillain-Barré syndrome. Schleicher GK; Black A; Mochan A; Richards GA Crit Care Med; 2003 Jun; 31(6):1848-50. PubMed ID: 12794429 [TBL] [Abstract][Full Text] [Related]
38. [The effect of plasmapheresis and other immunomodulating therapies on the course of severe Guillain-Barré syndrome]. Hidasi E; Soltész P Orv Hetil; 2001 Feb; 142(7):335-9. PubMed ID: 11243015 [TBL] [Abstract][Full Text] [Related]
39. Intravenously administered immunoglobulin in the treatment of childhood Guillain-Barré syndrome: a randomized trial. Korinthenberg R; Schessl J; Kirschner J; Mönting JS Pediatrics; 2005 Jul; 116(1):8-14. PubMed ID: 15995024 [TBL] [Abstract][Full Text] [Related]
40. Multiple cerebral infarctions after intravenous immunoglobulin for Guillain-Barré syndrome: two case reports and review of the literature. Wang W; Feng C; Liu Y; Tao Y; Bi X; Hou X Front Immunol; 2024; 15():1433240. PubMed ID: 39108266 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]